|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Breast Cancer | |||||
| Lymphoma | |||||
| Neoplasm | |||||
| Prostatic Neoplasm | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Breast Neoplasms | |||||
| Neoplasms | |||||
| Prostatic Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Breast Diseases | |||||
| Genital Diseases, Male | |||||
| Genital Neoplasms, Male | |||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Lymphatic Diseases | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Prostatic Diseases | |||||
| Skin Diseases | |||||
| Urogenital Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| 7-hydroxystaurosporine (UCN-01) | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| 7-hydroxystaurosporine | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Protein Kinase Inhibitors | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| National Cancer Institute (NCI) | |||||